Literature DB >> 8649815

Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion.

J Chen1, A Nachabah, C Scherer, P Ganju, A Reith, R Bronson, H E Ruley.   

Abstract

The present study characterized a mutation in the Eck receptor tyrosine kinase gene induced by the U3betageo gene trap retrovirus. The mutation (eck(i)) was identified during an in vitro screen for proviruses that disrupt developmentally regulated genes in cultured ES cells. The germ-line eck(i) fusion gene was expressed in blastocyst and later restricted to the primitive streak, node and to regions of the hindbrain in 6.5-10.5 day embryos. This is identical to the pattern of Eck gene expression as determined by either in situ hybridization or immunostaining, suggesting that expression of the Eck promoter was not affected by provirus integration. The provirus inserted approximately 8 kb upstream of the 5' end of the published cDNA sequence, and 1.8 kb downstream of an alternatively spliced 5' exon. The eck(i) allele is essentially a null mutation since mutant mice are severely deficient for Eck protein as determined by Western blot analysis and in vitro kinase assays. Nevertheless, mice homozygous for the mutation did not exhibit any discernable phenotype. These results suggest that other members of the Eph family of receptor tyrosine kinases can functionally compensate for loss of Eck.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649815

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Activation of cryptic 3' splice sites within introns of cellular genes following gene entrapment.

Authors:  Anna B Osipovich; Erica K White-Grindley; Geoffrey G Hicks; Michael J Roshon; Christian Shaffer; Jason H Moore; H Earl Ruley
Journal:  Nucleic Acids Res       Date:  2004-05-20       Impact factor: 16.971

Review 2.  Functional genomics of the murine immune system.

Authors:  H E Ruley
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Factors controlling cardiac neural crest cell migration.

Authors:  Margaret L Kirby; Mary R Hutson
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

4.  JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

Authors:  Wenqiang Song; Yufang Ma; Jialiang Wang; Dana Brantley-Sieders; Jin Chen
Journal:  Cancer Res       Date:  2014-03-07       Impact factor: 12.701

Review 5.  Eph-dependent cell-cell adhesion and segregation in development and cancer.

Authors:  Eva Nievergall; Martin Lackmann; Peter W Janes
Journal:  Cell Mol Life Sci       Date:  2011-12-28       Impact factor: 9.261

6.  Hypomorphic mutation in hnRNP U results in post-implantation lethality.

Authors:  Michael J Roshon; H Earl Ruley
Journal:  Transgenic Res       Date:  2005-04       Impact factor: 2.788

Review 7.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

8.  Dual targeting of EphA2 and FAK in ovarian carcinoma.

Authors:  Mian M K Shahzad; Chunhua Lu; Jeong-Won Lee; Rebecca L Stone; Rahul Mitra; Lingegowda S Mangala; Yiling Lu; Keith A Baggerly; Christopher G Danes; Alpa M Nick; Jyotsnabaran Halder; Hye-Sun Kim; Pablo Vivas-Mejia; Charles N Landen; Gabriel Lopez-Berestein; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2009-06-24       Impact factor: 4.742

9.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

Review 10.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.

Authors:  Michael S Kinch; Kelly Carles-Kinch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.